Key points from article :
BiondVax Pharmaceuticals is currently holding phase 3 clinical trials for the universal influenza vaccine.
Phase 3 double-blind placebo-controlled trials recruited around 12,400 participants.
Trials are being conducted in 83 hospitals across seven Eastern European countries.
BiondVax received investments from government bodies, private companies, funds over the years.
Vaccine combines 9 conserved epitopes into one protein.
Protein then can be used to invoke a much more expansive response towards the virus.
Vaccine is created in a lab using an engineered E. coli bacterium.
Mission is to reveal how many of the control group contracted flu compared to the vaccine group.
